JP2020513806A5 - - Google Patents

Download PDF

Info

Publication number
JP2020513806A5
JP2020513806A5 JP2019550560A JP2019550560A JP2020513806A5 JP 2020513806 A5 JP2020513806 A5 JP 2020513806A5 JP 2019550560 A JP2019550560 A JP 2019550560A JP 2019550560 A JP2019550560 A JP 2019550560A JP 2020513806 A5 JP2020513806 A5 JP 2020513806A5
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
nos
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019550560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513806A (ja
JP7216424B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2018/079109 external-priority patent/WO2018166495A1/en
Publication of JP2020513806A publication Critical patent/JP2020513806A/ja
Publication of JP2020513806A5 publication Critical patent/JP2020513806A5/ja
Application granted granted Critical
Publication of JP7216424B2 publication Critical patent/JP7216424B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019550560A 2017-03-15 2018-03-15 新規の抗ＴｒｋＢ抗体 Active JP7216424B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017076728 2017-03-15
CNPCT/CN2017/076728 2017-03-15
PCT/CN2018/079109 WO2018166495A1 (en) 2017-03-15 2018-03-15 Novel anti-trkb antibodies

Publications (3)

Publication Number Publication Date
JP2020513806A JP2020513806A (ja) 2020-05-21
JP2020513806A5 true JP2020513806A5 (https=) 2021-05-06
JP7216424B2 JP7216424B2 (ja) 2023-02-01

Family

ID=63521750

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019550560A Active JP7216424B2 (ja) 2017-03-15 2018-03-15 新規の抗ＴｒｋＢ抗体

Country Status (5)

Country Link
US (2) US10941203B2 (https=)
EP (2) EP3596126A4 (https=)
JP (1) JP7216424B2 (https=)
CN (2) CN110753702B (https=)
WO (1) WO2018166495A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110753702B (zh) * 2017-03-15 2022-09-20 清华大学 抗trkb抗体
US11066474B2 (en) * 2017-11-30 2021-07-20 Regeneron Pharmaceuticals, Inc. Anti-TrkB monoclonal antibodies and methods of use
CN110881570B (zh) * 2018-09-10 2023-05-02 廖亭彰 饲料添加剂及包含其的饲料
CN110812532A (zh) * 2019-08-20 2020-02-21 中山大学 一种靶向促进皮质脊髓束连接以修复脊髓损伤的组织工程支架的构建方法
EP4232474A1 (en) 2020-10-21 2023-08-30 Boehringer Ingelheim International GmbH Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases
CN118251415A (zh) * 2021-10-29 2024-06-25 清华大学 用于治疗或诊断精神分裂症的方法和产品
WO2023125485A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkB ANTIBODY AND APPLICATION THEREOF
IL315955A (en) 2022-03-30 2024-11-01 Peptidream Inc Peptide complex having trkb binding activity
WO2024081918A1 (en) 2022-10-14 2024-04-18 Talem Therapeutics Llc Anti-trkb/cd3 antibodies and uses thereof
CN119161442B (zh) * 2024-06-13 2026-04-07 厦门大学 一种TrkB靶向多肽及其应用
CN120665203B (zh) * 2025-06-18 2026-03-27 广东优赛生物医药科技有限公司 一种药物组合物及其在治疗中枢性肥胖中的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
CA2412494C (en) * 2000-06-22 2012-10-23 Genentech, Inc. Agonist anti-trk-c monoclonal antibodies
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US7244592B2 (en) 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
GT200600240A (es) 2005-06-06 2007-03-14 Anticuerpos monoclonales anti-trkb y usos de los mismos
WO2010086828A2 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
WO2011103667A1 (en) * 2010-02-26 2011-09-01 6452728 Canada Inc. Agonistic antibodies to trkb receptors and uses thereof
US9200080B2 (en) * 2010-09-03 2015-12-01 Horacio Uri Saragovi Agonistic antibodies to TrkC receptors and uses thereof
KR20180037994A (ko) * 2015-07-28 2018-04-13 오토노미, 인코포레이티드 TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법
JP7039468B2 (ja) * 2015-11-17 2022-03-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 神経およびその他の障害の処置のための結合アゴニスト
EP3452088A4 (en) 2016-05-03 2020-04-15 The Scripps Research Institute TRKB AGONIST ANTIBODIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
AU2017290256A1 (en) * 2016-06-29 2019-01-17 Otonomy, Inc. Triglyceride otic formulations and uses thereof
US9914781B1 (en) * 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
CN110753702B (zh) * 2017-03-15 2022-09-20 清华大学 抗trkb抗体

Similar Documents

Publication Publication Date Title
JP2020513806A5 (https=)
IL273424B2 (en) Novel bispecific cd3/cd19 polypeptide complexes
JP7306660B2 (ja) ＲＧＭａ結合タンパク質及びその使用
JP6342333B2 (ja) α−シヌクレインを認識するヒト化抗体
KR102602502B1 (ko) 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도
JP2021042257A5 (https=)
JP7626416B2 (ja) 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法
JP2019527194A5 (https=)
JP7039468B2 (ja) 神経およびその他の障害の処置のための結合アゴニスト
JP2022533432A5 (https=)
JP2020529473A5 (https=)
US11124568B1 (en) CD3/CD25 antibodies for neuro-immune diseases
JP2023537761A5 (https=)
Huang et al. Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule A to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models
ME01075B (me) Antitijela
JP7610767B2 (ja) レット症候群の処置のためのセマフォリン４ｄ結合分子の使用
US20230101618A1 (en) Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders
JP2023552919A5 (https=)
WO2026030311A1 (en) Use of semaphorin-4d inhibitory molecules to treat cognitive impairment
WO2025079006A9 (en) Anti-trka antibodies and uses thereof
AU2024360558A1 (en) Anti-trka antibodies and uses thereof
KR20240063995A (ko) 신경퇴행성 장애를 치료하기 위한 항-세마포린-4d 결합 분자의 사용을 위한 예측 결과 프로파일링
TH75038B (th) โมโนโคลนอลแอนติบอดีต้านโปรตีน rgm a และการใช้ของสิ่งนั้น
TH1801007500A (th) แอนติบอดีต่อแอลฟ่า-ซินนิวคลีอินและการใช้ของสารนี้
TH145220A (th) โมโนโคลนอลแอนติบอดีต้านโปรตีน rgm a และการใช้ของสิ่งนั้น